Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2009

01.03.2009 | HEPATOBILIARY AND PANCREATIC TUMORS

Surgical Treatments and Prognoses of Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma

verfasst von: Ki Hun Kim, MD, PhD, Sung Gyu Lee, MD, PhD, Eun Hwa Park, MD, Shin Hwang, MD, PhD, Chul Soo Ahn, MD, PhD, Deok Bog Moon, MD, PhD, Tae Yong Ha, MD, PhD, Gi Won Song, MD, Dong Hwan Jung, MD, PhD, Kang Mo Kim, MD, PhD, Young Suk Lim, MD, PhD, Han Chu Lee, MD, PhD, Young Hwa Chung, MD, PhD, Yung Sang Lee, MD, PhD, Dong Jin Suh, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Combined hepatocellular carcinoma and cholangiocarcinoma is a very rare form of primary liver cancer containing components of both tumor types. We evaluated the effectiveness of surgical treatment and factors related to survival and recurrence.

Patients and Methods

Of the 2427 patients who underwent hepatectomy or liver transplantation because of a primary hepatic malignancy from January 1989 to July 2006 at the Asan Medical Center, Seoul, Korea, 29 had hepatocellular carcinoma and cholangiocarcinoma as a single mixed or transitional tumor. Their medical records were retrospectively reviewed.

Results

Disease-free survival rates at 6 months, 1 year, and 3 years were 51.1%, 38.3%, and 25.6%, respectively. Univariate analysis showed that CA 19–9 above 37 U/ml was predictive of low overall survival (P = .03) and that TNM stage was significantly associated with disease-free survival (P = .04).

Conclusions

Patients with combined hepatocellular carcinoma and cholangiocarcinoma had poor postoperative survival rates. High CA 19–9 level was associated with poorer survival, suggesting that the cholangiocarcinoma portion may be a major determining factor for patient prognosis. Aggressive surgical treatment, including lymph node dissection, may improve survival in patients suspected of or diagnosed with these tumors.
Literatur
1.
Zurück zum Zitat Goodman ZD, Ishak KG, Langloss JM, et al. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer. 1985;55:124–5.PubMedCrossRef Goodman ZD, Ishak KG, Langloss JM, et al. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer. 1985;55:124–5.PubMedCrossRef
2.
Zurück zum Zitat Gibson JB. Histological typing of the liver. International histological classification of tumors. No. 20. Geneva: WHO; 1978. p. 19–30. Gibson JB. Histological typing of the liver. International histological classification of tumors. No. 20. Geneva: WHO; 1978. p. 19–30.
3.
Zurück zum Zitat Ishak KG, Anthony PP, Sobin LH. Histological typing of the liver. International histological classification of tumors. WHO. 2nd ed. Hong Kong: Springer-Verlag; 1994. Ishak KG, Anthony PP, Sobin LH. Histological typing of the liver. International histological classification of tumors. WHO. 2nd ed. Hong Kong: Springer-Verlag; 1994.
4.
Zurück zum Zitat The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Fourteenth National Primary Liver Cancer Tracking Survey Report (1996–1997) (in Japanese). Kyoto: Shinkou; 2000. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Fourteenth National Primary Liver Cancer Tracking Survey Report (1996–1997) (in Japanese). Kyoto: Shinkou; 2000.
5.
Zurück zum Zitat Ng IO, Shek TW, Nicholls J, et al. Combined hepatocellular-cholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol. 1998;13:34–40.PubMedCrossRef Ng IO, Shek TW, Nicholls J, et al. Combined hepatocellular-cholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol. 1998;13:34–40.PubMedCrossRef
6.
Zurück zum Zitat Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol. 1949;25:647–55.PubMed Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol. 1949;25:647–55.PubMed
7.
Zurück zum Zitat Yamaoka Y, Arii S, Okita K, et al., Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan. Report 13. Acta Hepatol Jpn. 1999;40:288–300. Yamaoka Y, Arii S, Okita K, et al., Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan. Report 13. Acta Hepatol Jpn. 1999;40:288–300.
8.
Zurück zum Zitat Maeda T, Adachi E, Kajiyama K, et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol. 1995;26:956–64.PubMedCrossRef Maeda T, Adachi E, Kajiyama K, et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol. 1995;26:956–64.PubMedCrossRef
9.
Zurück zum Zitat Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120–5.PubMedCrossRef Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120–5.PubMedCrossRef
10.
Zurück zum Zitat Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94:2040–6.PubMedCrossRef Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94:2040–6.PubMedCrossRef
11.
Zurück zum Zitat Kawasaki S, Makuuchi M, Miyagawa S, et al. Radical operation after portal embolization for tumor of hilar bile duct. J Am Coll Surg. 1994;178:480–6.PubMed Kawasaki S, Makuuchi M, Miyagawa S, et al. Radical operation after portal embolization for tumor of hilar bile duct. J Am Coll Surg. 1994;178:480–6.PubMed
12.
Zurück zum Zitat Taguchi J, Nakashima O, Tanaka M, et al. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 1996; 11:758–64.PubMedCrossRef Taguchi J, Nakashima O, Tanaka M, et al. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 1996; 11:758–64.PubMedCrossRef
13.
Zurück zum Zitat Liu CL, Fan ST, Lo CM, et al. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg. 2003;138:86–90.PubMedCrossRef Liu CL, Fan ST, Lo CM, et al. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg. 2003;138:86–90.PubMedCrossRef
14.
Zurück zum Zitat Edmondson H, Peters RL. Neoplasms of liver. In: Schiff L, Schoff E, editors. Disease of the Liver. 5th ed. Philadelphia: Lippincott; 1982. Edmondson H, Peters RL. Neoplasms of liver. In: Schiff L, Schoff E, editors. Disease of the Liver. 5th ed. Philadelphia: Lippincott; 1982.
15.
Zurück zum Zitat Kojiro M. Pathomorphology of advanced hepatocellular carcinoma. In: Tobe T, et al., editors. Primary liver cancer in Japan. Tokyo: Springer-Verlag; 1992. p. 31–7. Kojiro M. Pathomorphology of advanced hepatocellular carcinoma. In: Tobe T, et al., editors. Primary liver cancer in Japan. Tokyo: Springer-Verlag; 1992. p. 31–7.
16.
Zurück zum Zitat Imai Y, Oda H, Arai M, et al. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas. Jpn J Cancer Res. 1996;87:1056–62.PubMed Imai Y, Oda H, Arai M, et al. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas. Jpn J Cancer Res. 1996;87:1056–62.PubMed
17.
Zurück zum Zitat Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33:283–7.PubMedCrossRef Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33:283–7.PubMedCrossRef
18.
Zurück zum Zitat Tomimatsu M, Ishiguro N, Taniai M, et al. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer. 1993;72:683–8.PubMedCrossRef Tomimatsu M, Ishiguro N, Taniai M, et al. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer. 1993;72:683–8.PubMedCrossRef
19.
Zurück zum Zitat Asayama Y, Taguchi Ki K, Aishima Si S, et al. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin. Liver Int. 2002;22:43–50.CrossRef Asayama Y, Taguchi Ki K, Aishima Si S, et al. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin. Liver Int. 2002;22:43–50.CrossRef
20.
Zurück zum Zitat Lee WS, Lee KW, Heo JS, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006;36:892–7.PubMedCrossRef Lee WS, Lee KW, Heo JS, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006;36:892–7.PubMedCrossRef
21.
Zurück zum Zitat Uenishi T, Hirohashi K, Shuto T, et al. Surgery for mixed hepatocellular and cholangiocellular carcinoma. Hepatogastroenterology. 2000;47:832–4.PubMed Uenishi T, Hirohashi K, Shuto T, et al. Surgery for mixed hepatocellular and cholangiocellular carcinoma. Hepatogastroenterology. 2000;47:832–4.PubMed
22.
Zurück zum Zitat Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. Ann Intern Med. 1967; 67:337–48.PubMed Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. Ann Intern Med. 1967; 67:337–48.PubMed
23.
Zurück zum Zitat Weinbren K, Mutum SS. Pathological aspects of cholangiocarcinoma. J Pathol. 1983;139:217–38.PubMedCrossRef Weinbren K, Mutum SS. Pathological aspects of cholangiocarcinoma. J Pathol. 1983;139:217–38.PubMedCrossRef
24.
Zurück zum Zitat Nakamura S, Suzuki S, Sakaguchi T, et al. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma. Cancer. 1996;78:1671–6.PubMedCrossRef Nakamura S, Suzuki S, Sakaguchi T, et al. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma. Cancer. 1996;78:1671–6.PubMedCrossRef
25.
Zurück zum Zitat Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol. 2002;26:989–97.PubMedCrossRef Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol. 2002;26:989–97.PubMedCrossRef
26.
Zurück zum Zitat Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology. 1993;40:328–32.PubMed Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology. 1993;40:328–32.PubMed
27.
Zurück zum Zitat Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996;83:1219–22.PubMedCrossRef Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996;83:1219–22.PubMedCrossRef
28.
Zurück zum Zitat Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229:790–800.PubMedCrossRef Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229:790–800.PubMedCrossRef
29.
Zurück zum Zitat Nishie A, Yoshimitsu K, Asayama Y, et al. Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings. AJR Am J Roentgenol. 2005;184:1157–62.PubMed Nishie A, Yoshimitsu K, Asayama Y, et al. Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings. AJR Am J Roentgenol. 2005;184:1157–62.PubMed
Metadaten
Titel
Surgical Treatments and Prognoses of Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma
verfasst von
Ki Hun Kim, MD, PhD
Sung Gyu Lee, MD, PhD
Eun Hwa Park, MD
Shin Hwang, MD, PhD
Chul Soo Ahn, MD, PhD
Deok Bog Moon, MD, PhD
Tae Yong Ha, MD, PhD
Gi Won Song, MD
Dong Hwan Jung, MD, PhD
Kang Mo Kim, MD, PhD
Young Suk Lim, MD, PhD
Han Chu Lee, MD, PhD
Young Hwa Chung, MD, PhD
Yung Sang Lee, MD, PhD
Dong Jin Suh, MD, PhD
Publikationsdatum
01.03.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0278-3

Weitere Artikel der Ausgabe 3/2009

Annals of Surgical Oncology 3/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.